FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013181711> ?p ?o ?g. }

• W2013181711 endingPage "1465" @default.
• W2013181711 startingPage "1456" @default.
• W2013181711 abstract "Background Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized. Concerns have been raised over the possible deleterious effect of long-term therapy with inhaled corticosteroids (ICSs) on bone density in this population. Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol (SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe COPD in the TOwards a Revolution in COPD Health (TORCH) study. Methods A randomized, double-blind, parallel-group, placebo-controlled study conducted at 88 US centers involving 658 patients (a subset of 6,184 international subjects in TORCH). Therapy with placebo, SAL (50 μg), FP (500 μg), or SFC (SAL 50 μg/FP 500 μg) twice daily was administered for 3 years. Baseline and yearly measurements of BMD at the hip and lumbar spine were performed. The incidence of traumatic and nontraumatic bone fractures was recorded. Results At baseline, 18% of men and 30% of women had osteoporosis, and 42% of men and 41% of women had osteopenia based on BMD assessments. Forty-three percent of subjects completed all testing. The changes in BMD at the hip and lumbar spine over 3 years were small. No significant differences were observed between treatment arms (adjusted mean percent change from baseline at hip was −3.1% for placebo, −1.7% for SAL, −2.9% for FP, and −3.2% for SFC therapy, respectively; while, the corresponding changes for the lumbar spine were 0, 1.5%, −0.3%, and −0.3% for placebo, respectively, SAL, FP, and SFC therapy). The incidence of fractures was low and was similar for all treatments (5.1% to 6.3%). Conclusions Osteoporosis is highly prevalent in patients with COPD, irrespective of gender. In the TORCH study, no significant effect on BMD was detected for ICS therapy compared with placebo. Trial registration ClinicalTrials.gov Identifier: NTC00268216 Osteoporosis is common in patients with COPD, but its prevalence and progression are not well characterized. Concerns have been raised over the possible deleterious effect of long-term therapy with inhaled corticosteroids (ICSs) on bone density in this population. Here, we investigated the long-term effects of therapy with fluticasone propionate (FP) alone, salmeterol (SAL) alone, and a SAL/FP combination (SFC) on bone mineral density (BMD) and bone fractures in patients with moderate-to-severe COPD in the TOwards a Revolution in COPD Health (TORCH) study. A randomized, double-blind, parallel-group, placebo-controlled study conducted at 88 US centers involving 658 patients (a subset of 6,184 international subjects in TORCH). Therapy with placebo, SAL (50 μg), FP (500 μg), or SFC (SAL 50 μg/FP 500 μg) twice daily was administered for 3 years. Baseline and yearly measurements of BMD at the hip and lumbar spine were performed. The incidence of traumatic and nontraumatic bone fractures was recorded. At baseline, 18% of men and 30% of women had osteoporosis, and 42% of men and 41% of women had osteopenia based on BMD assessments. Forty-three percent of subjects completed all testing. The changes in BMD at the hip and lumbar spine over 3 years were small. No significant differences were observed between treatment arms (adjusted mean percent change from baseline at hip was −3.1% for placebo, −1.7% for SAL, −2.9% for FP, and −3.2% for SFC therapy, respectively; while, the corresponding changes for the lumbar spine were 0, 1.5%, −0.3%, and −0.3% for placebo, respectively, SAL, FP, and SFC therapy). The incidence of fractures was low and was similar for all treatments (5.1% to 6.3%). Osteoporosis is highly prevalent in patients with COPD, irrespective of gender. In the TORCH study, no significant effect on BMD was detected for ICS therapy compared with placebo." @default.
• W2013181711 created "2016-06-24" @default.
• W2013181711 creator A5000958944 @default.
• W2013181711 creator A5007976050 @default.
• W2013181711 creator A5014934142 @default.
• W2013181711 creator A5024191623 @default.
• W2013181711 creator A5028461016 @default.
• W2013181711 creator A5047181213 @default.
• W2013181711 creator A5063907950 @default.
• W2013181711 creator A5070315113 @default.
• W2013181711 creator A5083312029 @default.
• W2013181711 date "2009-12-01" @default.
• W2013181711 modified "2023-09-25" @default.
• W2013181711 title "Prevalence and Progression of Osteoporosis in Patients With COPD" @default.
• W2013181711 cites W176029630 @default.
• W2013181711 cites W1815612258 @default.
• W2013181711 cites W1939805807 @default.
• W2013181711 cites W1945464131 @default.
• W2013181711 cites W1974201106 @default.
• W2013181711 cites W1982682585 @default.
• W2013181711 cites W2006193143 @default.
• W2013181711 cites W2020965858 @default.
• W2013181711 cites W2059375401 @default.
• W2013181711 cites W2094203991 @default.
• W2013181711 cites W2100607777 @default.
• W2013181711 cites W2102765172 @default.
• W2013181711 cites W2109428979 @default.
• W2013181711 cites W2115118204 @default.
• W2013181711 cites W2120629366 @default.
• W2013181711 cites W2120794490 @default.
• W2013181711 cites W2133119676 @default.
• W2013181711 cites W2133390997 @default.
• W2013181711 cites W2138715818 @default.
• W2013181711 cites W2142243105 @default.
• W2013181711 cites W2142724633 @default.
• W2013181711 cites W2148761096 @default.
• W2013181711 cites W2159480781 @default.
• W2013181711 cites W2160611282 @default.
• W2013181711 cites W2268275976 @default.
• W2013181711 cites W2322866941 @default.
• W2013181711 cites W2338308982 @default.
• W2013181711 doi "https://doi.org/10.1378/chest.08-3016" @default.
• W2013181711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19581353" @default.
• W2013181711 hasPublicationYear "2009" @default.
• W2013181711 type Work @default.
• W2013181711 sameAs 2013181711 @default.
• W2013181711 citedByCount "223" @default.
• W2013181711 countsByYear W20131817112012 @default.
• W2013181711 countsByYear W20131817112013 @default.
• W2013181711 countsByYear W20131817112014 @default.
• W2013181711 countsByYear W20131817112015 @default.
• W2013181711 countsByYear W20131817112016 @default.
• W2013181711 countsByYear W20131817112017 @default.
• W2013181711 countsByYear W20131817112018 @default.
• W2013181711 countsByYear W20131817112019 @default.
• W2013181711 countsByYear W20131817112020 @default.
• W2013181711 countsByYear W20131817112021 @default.
• W2013181711 countsByYear W20131817112022 @default.
• W2013181711 countsByYear W20131817112023 @default.
• W2013181711 crossrefType "journal-article" @default.
• W2013181711 hasAuthorship W2013181711A5000958944 @default.
• W2013181711 hasAuthorship W2013181711A5007976050 @default.
• W2013181711 hasAuthorship W2013181711A5014934142 @default.
• W2013181711 hasAuthorship W2013181711A5024191623 @default.
• W2013181711 hasAuthorship W2013181711A5028461016 @default.
• W2013181711 hasAuthorship W2013181711A5047181213 @default.
• W2013181711 hasAuthorship W2013181711A5063907950 @default.
• W2013181711 hasAuthorship W2013181711A5070315113 @default.
• W2013181711 hasAuthorship W2013181711A5083312029 @default.
• W2013181711 hasConcept C120665830 @default.
• W2013181711 hasConcept C121332964 @default.
• W2013181711 hasConcept C126322002 @default.
• W2013181711 hasConcept C142724271 @default.
• W2013181711 hasConcept C1862650 @default.
• W2013181711 hasConcept C204787440 @default.
• W2013181711 hasConcept C27081682 @default.
• W2013181711 hasConcept C2776541429 @default.
• W2013181711 hasConcept C2776780178 @default.
• W2013181711 hasConcept C2776804153 @default.
• W2013181711 hasConcept C2776886416 @default.
• W2013181711 hasConcept C2777083390 @default.
• W2013181711 hasConcept C2779028295 @default.
• W2013181711 hasConcept C2779329777 @default.
• W2013181711 hasConcept C2908647359 @default.
• W2013181711 hasConcept C61511704 @default.
• W2013181711 hasConcept C71924100 @default.
• W2013181711 hasConcept C99454951 @default.
• W2013181711 hasConceptScore W2013181711C120665830 @default.
• W2013181711 hasConceptScore W2013181711C121332964 @default.
• W2013181711 hasConceptScore W2013181711C126322002 @default.
• W2013181711 hasConceptScore W2013181711C142724271 @default.
• W2013181711 hasConceptScore W2013181711C1862650 @default.
• W2013181711 hasConceptScore W2013181711C204787440 @default.
• W2013181711 hasConceptScore W2013181711C27081682 @default.
• W2013181711 hasConceptScore W2013181711C2776541429 @default.
• W2013181711 hasConceptScore W2013181711C2776780178 @default.
• W2013181711 hasConceptScore W2013181711C2776804153 @default.
• W2013181711 hasConceptScore W2013181711C2776886416 @default.

• next